EGFR and glioblastoma: For example, 18F-FDG PET scans revealed EGFR-driven glucose utilization in a subset of GBM tumors, which exhibited decreased glucose metabolism after acute EGFR inhibition and classified as metabolic responders, indicating that EGFR-targeted treatment is a promising metabolic therapy [114].